SCHEMBL4883173

SCHEMBL4883173

CN1CCN(CC(O)C(O)(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.58
CHRM4 P08173 3/20 0.52
CHRM5 P08912 3/20 0.52
CHRM3 P20309 3/20 0.52
CHRM2 P08172 2/20 0.52
CHRM1 P11229 2/20 0.52
ATM Q13315 1/20 0.49
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
POLB P06746 2/20 0.45
MC4R P32245 1/20 0.45
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.44
LMNA P02545 1/20 0.44
PLK1 P53350 2/20 0.42
TSHR P16473 1/20 0.42
KCNA5 P22460 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14003857 0.86 GAA (0.56) GAACHRM4CHRM5CHRM3CHRM2
SCHEMBL14003867 0.81 GAA (0.51) GAACHRM4CHRM5CHRM3CHRM2
SCHEMBL4883044 0.81 CHRM2 (0.52) CHRM4CHRM5CHRM3CHRM2CHRM1
SCHEMBL4889264 0.79 TSHR (0.53) GAACHRM4CHRM5CHRM3CHRM2
SCHEMBL4887061 0.77 CHRM2 (0.48) CHRM4CHRM5CHRM3CHRM2CHRM1
SCHEMBL4887153 0.76 CHRM3 (0.50) GAACHRM4CHRM5CHRM3CHRM2
SCHEMBL3444359 0.75 GAA (0.50) GAACHRM4CHRM5CHRM3CHRM2
SCHEMBL352281 0.73 GAA (1.00) GAAALDH1A1MEN1KMT2AKDM4E
SCHEMBL11884527 0.73 HTT (0.71) GAACHRM4CHRM5CHRM3CHRM2
SCHEMBL4889924 0.72 KDM4E (0.58) CHRM4CHRM5CHRM3CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US claimed
EP-1794161-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-13 EP claimed
WO-2006032994-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-03-30 WO claimed
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US disclosed
EP-1794161-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-13 EP disclosed
WO-2006032994-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280883-A1 Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 GAA 1606/4885CHRM4 4/4885CHRM5 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.